ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer

Summary

This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications